January 30, 2018 / 1:43 PM / in 7 minutes BRIEF-Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research Reuters Staff 1 Min Read 
Jan 30 (Reuters) - Vaxil Bio Ltd: 
* VAXIL COMPLETES OVERSUBSCRIBED FINANCING TO ADVANCE ITS CANCER IMMUNOTHERAPY RESEARCH AND DEVELOPMENT Source text for Eikon: Further company coverage: